130 likes | 147 Views
Watson for Oncology provides support for various cancer types including colorectal, lung, breast, gastric, cervical, ovarian, and prostate. It offers decision trees for treatment strategies based on patient characteristics and cancer stage.
E N D
Watson for Oncology Clinical support 17.5 Tom Eggebraaten, 2017
Watson for Oncology – Cancer coverage * 1st Line Metastatic in this table refers to patients who are newly diagnosed with metastatic disease ** Med Onc: includes chemotherapy, endocrine therapy and targeted therapy where appropriate *** Ovarian also includes Fallopian Tube, and Primary Peritoneal cancer
Watson Oncology – Lung cancer (Both Non-small cell and small cell histologies)
* Ovarian also includes Fallopian Tube, and Primary Peritoneal cancer Watson Oncology – Ovarian cancer*
Watson Oncology – Decision tree New Patient Patient Age Colon < 18 Supported Rectal >= 18 Pregnant? Yes Not Supported Supported No No Multiple Cancers? Cancer Type? Lung Prior Surgery? Yes Not Supported Yes IIIB No Targeted 1 Multiple Primary Tumors? Number Of Metastatic Sites? Prior Therapy*? Yes Stage? IV 2+ No Local Recurrence? Chemo or None I - IIIA Supported Yes No Not Supported Adenoid cystic Colloid Secretory Tubular Male 2+ Breast # of Metastatic Therapies? Gender? Histology? M Category Female Other M1 Supported M0 0-1 Gastric, Cervical, Ovarian (Next chart) * Prior therapy includes: chemotherapy, radiation therapy, targeted therapy or endocrine therapy
Watson Oncology – Decision tree Cancer Type Not Supported # of Metastatic Therapies? M Category Gastric 2+ M1 Supported M0 0 - 1 other Not Supported 3+ Squamous cell Adenocarcinoma Adenosquamous Small cell Gastric type Small cell # of Metastatic Therapies? Cervical Histology Cancer stage Histology 2 other IVB Supported I-IVA 0 - 1 other Not Supported 4+ # of Metastatic Therapies? Ovarian Histology Cancer stage High grade serous IV Supported I-III 0 - 3
Watson Oncology – Decision tree Cancer Type other Not Supported 3+ # of Metastatic Therapies? Prostate Histology Adenocarcinoma Supported 0 - 2